JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corbel, M.
Right arrow Articles by Lagente, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corbel, M.
Right arrow Articles by Lagente, V.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Lung Diseases

Vol. 301, Issue 1, 258-265, April 2002

The Selective Phosphodiesterase 4 Inhibitor RP 73-401 Reduced Matrix Metalloproteinase 9 Activity and Transforming Growth Factor-beta Release During Acute Lung Injury in Mice: The Role of the Balance Between Tumor Necrosis Factor-alpha and Interleukin-10

Marianne Corbel, Noëlla Germain, Jérôme Lanchou, Sophie Molet, Patricia M. R. e Silva, Marco A. Martins, Elisabeth Boichot and Vincent Lagente

Institut National de la Santé et de la Recherche Medicale U 456, Faculté des Sciences Pharmaceutiques et Biologiques, Université de Rennes 1, Rennes, France (M.C., N.G., J.L., S.M., E.B., V.L.); and Departamento de Fisiologia e Farmacodinâmica, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil (P.M.R.e.S., M.A.M.)

Matrix metalloproteinases (MMPs) and transforming growth factor (TGF)-beta are involved in airway remodeling associated with the inflammatory process. In this study, we investigated the effect of RP 73-401 (piclamilast), a selective phosphodiesterase-4 inhibitor, on MMP-9 activity and TGF-beta production in two murine models of acute inflammation. In the first model, the lipopolysaccharide (LPS)-induced increase in neutrophils, MMP-9 activity, and tumor necrosis factor (TNF)-alpha and TGF-beta release in bronchoalveolar lavage (BAL) was significantly reduced by RP 73-401 pretreatment. In contrast, the BAL interleukin (IL)-10 level was decreased by LPS but restored by RP 73-401. IL-10 administration in LPS-exposed mice elicited a significant reduction in BAL neutrophilia, MMP-9 activity, and TNF-alpha release but not in TGF-beta production. In the second model, RP 73-401 inhibited BAL neutrophils but not MMP-9 activity and TGF-beta production that were induced by intranasal TNF-alpha . We demonstrated that RP 73-401 might modulate the expression of airway remodeling-associated mediators such as MMP-9 and TGF-beta and that this effect seemed to be at least partially mediated by the balance between TNF-alpha and IL-10.

0022-3565/02/3011-0258$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 FASEB J.Home page
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice
FASEB J, June 1, 2008; 22(6): 1849 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas
Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. Leclerc, V. Lagente, J-M. Planquois, C. Berthelier, M. Artola, T. Eichholtz, C. P. Bertrand, and F. Schmidlin
Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice
Eur. Respir. J., June 1, 2006; 27(6): 1102 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Videla, J. Vilaseca, C. Medina, M. Mourelle, F. Guarner, A. Salas, and J.-R. Malagelada
Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 940 - 945.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Oger, C. Mehats, E. Dallot, D. Cabrol, and M.-J. Leroy
Evidence for a Role of Phosphodiesterase 4 in Lipopolysaccharide-Stimulated Prostaglandin E2 Production and Matrix Metalloproteinase-9 Activity in Human Amniochorionic Membranes
J. Immunol., June 15, 2005; 174(12): 8082 - 8089.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Ariga, B. Neitzert, S. Nakae, G. Mottin, C. Bertrand, M. P. Pruniaux, S.-L. C. Jin, and M. Conti
Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation
J. Immunol., December 15, 2004; 173(12): 7531 - 7538.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.R.M. Rocco, D.P. Momesso, R.C. Figueira, H.C. Ferreira, R.A. Cadete, A. Legora-Machado, V.L.G. Koatz, L.M. Lima, E.J. Barreiro, and W.A. Zin
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury
Eur. Respir. J., July 1, 2003; 22(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
J. J. Atkinson and R. M. Senior
Matrix Metalloproteinase-9 in Lung Remodeling
Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 12 - 24.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.